![]() ![]() |
|
![]() |
There are several types of arthritis, each having both common and unique characteristics. Therefore determination of the specific arthritis present is necessary in order to construct a valuable health care program. Unique physiologic features of each patient such as metabolic type, allergies or sensitivities, digestive status, toxicity status, etc. must also be determined as these circumstances will influence the effectiveness of therapy or present conditions that must be first corrected before effective intervention can be introduced. Concurrent health conditions should be known such as diabetes, hypertension, renal disease, dysbiosis, circulatory problems, etc. for the same reasons. As I am sure you know some nutrients will not function optimally unless their metabolic avenues are clear of traffic. Detoxification, adequate hydration (40% of body weight in ounces daily without underlying cardiac, pulmonary or renal complications), reduction of allergic load, reduced sugar consumption, etc. will all “clear the road” for nutraceuticals to do their work in the best possible way. Exercise is also a major factor for all patients with arthritis. But the same exercise for all arthritis sufferers will not work either. Generally speaking, aerobic level activity will provide a good constitutional basis. For most patients with arthritis aquatic exercise seems to work the best. The buoyancy of the water helps mitigate gravitational and impact load on the joints while providing moderate resistance. There are many fine books that will give guidance in this area. Focusing the patient on proper form and the purpose for the exercise as well as challenging specific muscle groups or joints should be a focus for all physicians. Care must be taken not to over stress arthritic joints but this usually is not a problem. More often than not keeping the patient motivated when they do not immediately improve is a greater problem. Specific nutrients that are useful for those patients with
arthritis are the following. This is certainly not an exhaustive list as the
constellation of nutraceutical substances that address the various aspects of
arthritis is vast. All of these nutrients are not necessary for every patient so
let’s try to specify which is most valuable for specific patients. Glucosamine is an amino sugar component of chitin, heparan sulphate, chondroitin sulphate and many complex glycosaminoglycans (mucopolysaccharides). Proteoglycans are large carbohydrate-rich molecules present in virtually all cartilage and many connective tissues. Glucosamine sulfate provides the basic building block for cartilage matrix1. Proteoglycans are hydrophilic and provide resiliency, load distribution, shock absorption, and compressive resistance functions especially as it relates to joints. Loss of fluid content and degradation of type II collagen (the major collagen component of cartilage2) appears to be a key to the pathological process common in many forms of arthritis3,4. Early investigations of glucosamine sulfate appeared to demonstrate the ability of the substance to actually rebuild and restore thickness to joint cartilage. More recent studies regarding disease modification5 demonstrate glucosamine sulfate’s ability to prevent cartilage thickness loss6. There also appears to be an anti-inflammatory effect7 of glucosamine but in clinical trials has not worked as well as NSAIDs. Individuals taking NSAIDs and glucosamine concurrently have found less benefit than with glucosamine alone. This is hypothesized to be a consequence of COX suppression and therefore decreased availability of all eicosanoids within cartilaginous tissues. Glucosamine sulfate appears to be absorbed intact with one study indicating greater than 88% absorption8. Glucosamine sulfate is the form which has been studied in many clinical and laboratory trials, and it is this form that has been repeatedly demonstrated as effective9; however, it is believed that glucosamine HCl should be equally as effective. There has been some recent debate regarding blood sugar problems when giving glucosamine sulfate to diabetics10. There is currently no definitive answer as to the effect of glucosamine on blood glucose, as it has not been a primary outcome variable of any of the glucosamine studies. It should be noted that studies have demonstrated that the sugar portion of glucosamine is not metabolized through “normal” pathways. With all of these concepts in mind, treatment of most types of arthritis with glucosamine sulfate is appropriate although the most effective use is in patients with osteoarthritis. Therapeutic dosage of 1500 mg daily in divided doses is appropriate. Chondroitin Sulfate Chondroitin sulfate is a glycosaminoglycan that is a major component of the extracellular matrix and connective tissue of animals, found on the outside of the cell membranes of some animal cells. They are repeating polymers of glucuronic acid and sulphated Nacetyl- glucosamine residues that are highly hydrophilic and anionic. It was initially thought that chondroitin sulfate (because of its molecular size) would not be absorbed intact and therefore accounted for some of the failure in treatment. Recent studies have demonstrated chondroitin’s absorption and availability in the disaccharide form11; however, it is not as well absorbed as glucosamine. Chondroitin sulfate has a similar anti-inflammatory effect to glucosamine9 although other studies demonstrate that it may act via a different mechanism12,13. Many of the benefits attributed to glucosamine can also be related to chondroitin sulfate. Chondroitin appears to protect existing cartilage by decreasing water loss from the matrix and inhibiting the breakdown of cartilage by enzymatic reactions. Many recent studies have demonstrated combined glucosamine/chondroitin therapy seems to be more effective for certain individuals or types of arthritis14,15. Although glucosamine is a precursor for chondroitin synthesis and logic would seem to indicate that administration of glucosamine would address all cartilage maintenance and repair issues, this process requires a significant amount of metabolic energy. In some individuals there are circumstances where this metabolic energy is limited or unavailable, therefore administration of chondroitin may spare this metabolic pathway and help protect cartilage better than glucosamine sulfate. In my practice I have found that individuals with a
significant number of concurrent health conditions such as asthma, diabetes,
digestive disorders, etc. will respond more favorably using a combined
glucosamine/chondroitin formulation. I have also found that patients with
rheumatoid arthritis have better results using chondroitin sulfate with MSM than
glucosamine sulfate alone. Chondroitin sulfate should be given at 1500 mg daily
in divided doses. MSM is a source of organic sulfur found naturally in the human body and in many foods. It is the major metabolite of DMSO (dimethyl sulfoxide), is 34% elemental sulfur, and is the primary component that appears to be of the greatest benefit to the body16. While sulfur supports many functions, it is well known for maintaining connective tissue health and therefore supports those tissues with significant amounts of collagen and keratin such as ligaments, tendons, arteries and cartilage. Type II collagen degradation by enzymatic action is a major component in the pathogenesis of arthritis. MSM provides additional elemental sulfur to aid the body in the repair process of these tissues. MSM may support the body in regulating insulin production, improving skin smoothness and elasticity, regulating environmental and allergic sensitivities, enhancing bowel function and liver detoxification, and enhancing respiratory function16. Some studies have demonstrated immunosupportive effects of MSM17. Lastly sulfur is a key element necessary in the detoxification processes which is highly valuable in many patients with arthritis. Given this information, MSM is very useful in the treatment of most types of arthritis but RA patients seem to respond the best. Dosages vary from 850 to 3000 mg daily. Some authorities advocate even higher amounts. Bromelain Bromelain is a proteolytic enzyme complex derived from the stalk of the pineapple plant which demonstrates anti-edematous, anti-inflammatory, anti-thrombotic and fibrinolytic activities. Bromelain is absorbed intact through the GI mucosa with up to 40% being detected in the blood after consumption18. Bromelain’s therapeutic actions are only partially due to its enzymatic activity. It has several biologic effects including directly affecting bradykinin production19; selectively removing certain cell surface molecules that affect lymphocyte migration and activation20,21; has immunomodulating properties22; enhances T-cell responsiveness23; stimulates increased phagocytosis, pathogen killing capacity and reactive oxygen species production24; produces post-traumatic and post-surgical edema reduction25; and was able to induce increased natural killer cell activity in immuno compromised individuals26. Studies comparing bromelain’s anti-inflammatory effects against pharmaceuticals demonstrate greater levels of improvement and decreased dependency on analgesics27 with bromelain. All of this recent elucidation of the mechanisms of action of bromelain only goes to strengthen the therapeutic value and necessity of use in inflammatory disorders such as arthritis but should also include digestive disorders28, pulmonary disease, vascular disease, etc. The most effective dosage for bromelain is 5,000 m.c.u. (milk clotting units) - three times daily between meals. I have found that getting patients to take it twice daily is about the best they can do so I prescribe two twice daily. Bromelain must be taken on an empty stomach (two hours after or one hour before a meal) and be undenatured in order to have the desired effect for arthritis. Taken with meals bromelain is an excellent aid in protein digestion. Omega-3 Fatty Acids Fish source omega-3 (n-3) fatty acids have long been known for their cytoprotective capacity. In the past 10 years over 4500 studies have been performed on these valuable fats. They are cardioprotective reducing mortality significantly, anti-arrhythmic, induce lower triglycerides, reduce joint tenderness in RA patients, are anti-inflammatory, anti-tumorogenic, and anti-thrombotic29. Virtually all cell membrane phospholipids are composed of n-3 or n-6 fatty acids from which are derived the various components of the arachidonic acid cascade. Deficiency in either n-3 or n-6 fatty acids will cause imbalance in eicosanoid production30. Studies have demonstrated the following functions of n-3 fatty acids. A decrease in arachidonic acid concentrations with decreased clotting times and increased fibrinolysis31; decrease in multiple inflammatory markers in many conditions32,33; decrease in TNF and IL1 in chronic inflammatory diseases34; down-regulation of inflammation by enhancing IL10 expression35; reduced IL1 and LTB4 in many tissues36; and is a potent inhibitor of leukocyte adhesion receptor expression and leukocyte-endothelium interactions37. Omega-3 fatty acids exert effects outside of the eicosanoid synthesis pathways. The net effect of n-3 fatty acids is to reduce heart attack and disease risks29, stabilize myocardial membranes38, decrease cancer cell growth rates39, have anti-depressant effects (several major medical trials under way presently), and improve chronic inflammatory disease40. As it relates to arthritis, n-3 fatty acids will reduce inflammation and edema in joints as well as aid in the repair process of many of the damaged tissues. High doses are valuable especially in RA but also in OA during inflamed episodes. A word about
fatty acids. Many studies have demonstrated the need for balance in the
consumption of n-3 and n-6 fatty acids. A recent NIH survey states that the
average American consumes n-6/n-3 fatty acids in a 47:1 ratio whereas the proper
ratio for good cellular health is 7:1. Also the source of n-3 fatty acids should
be natural fish. There are many recent endeavors to prove that n-3 from
vegetable or grain sources are comparable to fish oil. Most plant sources of
omega-3 fatty acids do not provide EPA and DHA, the two major omega-3 fatty
acids found in fish sources. While fatty acids such as alpha- linolenic acid
(ALA) certainly have health benefits, it is not clear that they are metabolized
by the body in a fashion similar to EPA and DHA. We do not have data to show
that the data on fish oil supplementation can be completely replicated by
supplementing with plant sources of omega-3 fatty acids. Also be aware of the
“trans” problem which are fats mutated into the trans configuration by high
temperature processing and cooking. Be sure the n-3 you and your patients
consume are from a reliable source. Therapeutically valuable dose range is
2000-6000 mg daily in divided doses for arthritis29. As you can see
there are many alternative nutraceutical therapies that are as valuable as
medical therapies and in many ways superior since they work within the body’s
functions to produce improvements “naturally” instead of chemically. Many of
these substances work so well that the medical community is beginning to catch
on. 2 Miosge N; Hartmann M; Maelicke C; Herken R Expression of collagen type I and type II in consecutive stages of human osteoarthritis. Histochem Cell Biol 2004 Sep;122(3):229-36 ISSN: 0948-6143 3 Lindhorst E; Wachsmuth L; Kimmig N; Raiss R; Aigner T; Atley L; Eyre D Increase in degraded collagen type II in synovial fluid early in the rabbit meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2005 Feb;13(2):139-45 ISSN: 1063-4584 4 Jung M; Christgau S; Lukoschek M; Henriksen D; Richter W Increased urinary concentration of collagen type II Ctelopeptide fragments in patients with osteoarthritis. Pathobiology 2004;71(2):70-6 (ISSN: 1015-2008 5 Reginster JY; Bruyere O; Lecart MP; Henrotin Y Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Curr Opin Rheumatol 2003 Sep;15(5):651-5 ISSN: 1040-8711 6 Bruyere O; Pavelka K; Rovati LC; Deroisy R; Olejarova M; Gatterova J; Giacovelli G; Reginster JY Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004 Mar-Apr;11(2):138-43†ISSN: 1072-3714 7 Chou MM; Vergnolle N; McDougall JJ; Wallace JL; Marty S; Teskey V; Buret AG Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005 Apr;230(4):255-62 ISSN: 1535-3702 8 Setnikar I; Rovati LC Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 2001 Sep;51(9):699-725 ISSN: 0004-4172 9 Adebowale A; Du J; Liang Z; Leslie JL; Eddington ND The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002 Sep;23(6):217-25 ISSN: 0142-2782 10 Yu JG; Boies SM; Olefsky JM The effect of oral glucosamine sulfate on insulin sensitivity in human subjects. Diabetes Care 2003 Jun;26(6):1941-2 ISSN: 0149-5992 11 Adebowale A; Du J; Liang Z; Leslie JL; Eddington ND The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002 Sep;23(6):217-25 ISSN: 0142-2782 12 Baici A; Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate Chem Biol Interact 1984 Sep 1;51(1):1-11. 13 Bartolucci C, Cellai L, Corradini C, Corradini D, Lamba D, Velona I. Chondroprotective action of chondroitin sulfate on the digestion of hyaluronan by bovine testicular hyaluronidase Int J Tissue React 1991;13(6):311-317. 14 Chou MM; Vergnolle N; McDougall JJ; Wallace JL; Marty S; Teskey V; Buret AG Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005 Apr;230(4):255-62 ISSN: 1535-3702 15 Lippiello L; Woodward J; Karpman R; Hammad TA In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000 Dec;(381):229-40 ISSN: 0009-921X 16 Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev 2002 Feb;7(1):22-44 ISSN: 1089-5159 17 Morton JI, Siegel BV Effects of oral dimethyl sulfoxide and dimethyl sulfone on murine autoimmune lymphoproliferative disease. Proc Soc Exp Biol Med 1986 Nov;183(2)227-230 18 White RR, Crwaley FE, Vellini M, et.al. Bioavailability of 125I bromelain after oral administration to rats. Biopharm Drug Dispos 1988:9:397-403. 19 Taussin SI, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22:191-203. 20 Hale LP. Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice. Int Immunopharmacol 2004 Feb;4(2):255-64 ISSN: 1567-5769 21 Hale LP; Greer PK; Sempowski GD Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 2002 Aug;104(2):183-90 ISSN: 1521-6616 22 Maurer HR Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 2001 Aug;58(9):1234-45 ISSN: 1420-682X 23 Engwerda CR; Andrew D; Ladhams A; Mynott TL Bromelain modulates T cell and B cell immune responses in vitro and in vivo. Cell Immunol 2001 May 25;210(1):66-75 ISSN: 0008-8749 24 Brakebusch M; Wintergerst U; Petropoulou T; Notheis G; Husfeld L; Belohradsky BH; Adam D Dr. von Haunersches Kinderspital, Abtl. Bromelain is an accelerator of phagocytosis, respiratory burst and Killing of Candida albicans by human granulocytes and monocytes. Eur J Med Res 2001 May 29;6(5):193-200 ISSN: 0949-2321 25 Kamenicek V; Holan P; Franek P [Systemic enzyme therapy in the treatment and prevention of post-traumatic and postoperative swelling] Acta Chir Orthop Traumatol Cech 2001;68(1):45-9 ISSN: 0001-5415 26 Engwerda CR; Andrew D; Murphy M; Mynott TL Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol 2001 May 25;210(1):5-10 ISSN: 0008-8749 27 Akhtar NM; Naseer R; Farooqi AZ; Aziz W; Nazir M Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee—a double-blind prospective randomized study. Clin Rheumatol 2004 Oct;23(5):410- 5 ISSN: 0770-3198 28 Hale LP; Greer PK; Trinh CT; Gottfried MR Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease [epub ahead of print] Clin Immunol 2005 Jun 1; pS1521-6616 29 Covington MB. Omega-3 fatty acids. Am Fam Physician 2004 Jul 1;70(1):133-40 ISSN: 0002-838X 30 Koller M; Senkal M; Kemen M; Konig W; Zumtobel V; Muhr G Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery. Clin Nutr 2003 Feb;22(1):59-64 ISSN: 0261-5614 31 Cadroy Y, DuPout D, Doneau B. Arachidonic Acid enhances the tissue fraction expression of mononuclear cells by the cyclooxygenase 1 pathway; Beneficial effects of n-3 fatty acids. Journal of Immunology P6145-6150 (1998) 32 Vardar S; Buduneli E; Turkoglu O; Berdeli AH; Baylas H; Baskesen A; Atilla G Therapeutic versus prophylactic plus therapeutic administration of omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2004 Dec;75(12):1640-6 ISSN: 0022-3492 33 Vardar S; Buduneli E; Baylas H; Berdeli AH; Buduneli N; Atilla G Individual and combined effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on endotoxin-induced periodontitis in rats. J Periodontol 2005 Jan;76(1):99-106 ISSN: 0022-3492 34 Tamizi far B; Tamizi B Treatment of chronic fatigue syndrome by dietary supplementation with omega-3 fatty acids—a good idea? Med Hypotheses 2002 Mar;58(3):249-50 ISSN: 0306-9877 35 Sierra S; Lara-Villoslada F; Olivares M; Jimenez J; Boza J; Xaus J. [Il-10 expression is involved in the regulation of the immune response by omega 3 fatty acids] Nutr Hosp 2004 Nov-Dec;19(6):376-82 ISSN: 0212-1611 36 Simopoulos AP Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002 Dec;21(6):495-505 ISSN: 0731-5724 37 Sethi S. Inhibition of leukocyte-endothelial interactions by oxidized omega-3 fatty acids: a novel mechanism for the anti-inflammatory effects of omega-3 fatty acids in fish oil. Redox Rep 2002;7(6):369-78 ISSN: 1351-0002 38 O’Keefe JH; Harris WS From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000 Jun;75(6):607-14 ISSN: 0025-6196 39 Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr 2004 Dec;134(12 Suppl):3427S-3430S ISSN: 0022-3166 40 Stephensen CB Fish oil and inflammatory disease: is asthma the next target for n-3 fatty acid supplements? Nutr Rev 2004 Dec;62(12):486-9 ISSN: 0029-6643 41 Tanimoto K; Ohno S; Fujimoto K; Honda K; Ijuin C; Tanaka N; Doi T; Nakahara M; Tanne K Proinflammatory cytokines regulate the gene expression of hyaluronic acid synthetase in cultured rabbit synovial membrane cells. Connect Tissue Res 2001;42(3):187-95 ISSN: 0300-8207 42 Petrella RJ Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil 2005 Apr;84(4):278-83; quiz 284, 293 ISSN: 0894-9115 43 Nonaka T; Kikuchi H; Ikeda T; Okamoto Y; Hamanishi C; Tanaka S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol 2000 Apr;27(4):997-1004 ISSN: 0315-162X 44 McCarty MF; Russell AL; Seed MP. Sulfated glycosaminoglycans and glucosamine may synergize in promoting synovial hyaluronic acid synthesis. Med Hypotheses 2000 May;54(5):798-802 ISSN: 0306-9877 45 Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol 1999;73:153-264. 46 Cazzola M, Artivalle M, Sazzi-Puttini P, et al. Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study. Clin Exp Rheum 2000;18:571-578 47 Barnett ML, Kremmer JM, St. Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo- controlled trial. Arth Rheum 1998;41:290-7. 48 Mills S, Bone K. Principles and Practice of Phytotherapy. Churchill Livingstone 2000, p269-270, ISBN 0-443-060169 49 Nir Y, et al. Effects of an astaxanthin containing product on rheumatoid arthritis. J Amer Col Nutrition 2002 Ictiber;21(5):490.
Frozen Cellular Extracts •
Xtra-Cell •
Top Products
Development Team
Comprehensive Blood Testing and Laboratory Services
Featured Products Manufacturers
Members
|